Company News

CSC China plans to strengthen sales of media for Chinese biopharmaceuticals

Equipped with the latest automatic ‘high through put’ equipment for optimizing media for CHO cell lines

Ajinomoto (China) Co., Ltd. (President Tadahiro Kato, hereinafter referred to as Ajinomoto China), an affiliated company of 

Ajinomoto Genexine, a cell culture medium specialist, announced that it has opened a CSC in Shanghai, China.

Ajinomoto China plans to strengthen sales of biopharmaceutical media in the Chinese market by opening CELLiST Solution 

Center China (hereinafter referred to as CSC China), a customer center for the Chinese biopharmaceutical media business.

According to information disclosed at the opening ceremony held last month, the global market for media essential for cell 

culture in biopharmaceutical research, development and manufacturing is growing by more than 10% every year due to increased demand for antibody drugs or vaccines and the expansion of cell and gene therapy. is showing.

According to an Aranca survey, it is expected to grow to exceed $15 billion by 2030, and in particular, the Chinese bio market is expected to occupy $3 billion by 2030, with an annual market growth rate of 20% from 2025 to 2030. It is expected to reach. 

Demand for medium for CHO (Chinese Hamster Ovary) cell lines, which is becoming the mainstream medium for 

biopharmaceuticals, is also expected to rapidly increase.

In line with the growth of the Chinese biopharmaceutical media market, CSC China collaborated with Ajinomoto Co.,

Ltd. (CEO Fujie Taro, headquartered in Chuo-ku, Tokyo/hereinafter referred to as Ajinomoto) and its group company Ajinomoto 

Genexine (CEO Nakai Yuta, headquartered in Incheon, Korea) to produce media, including media. We will provide technical 

support focusing on process optimization and customization.

Shanghai Ajinomoto Amino Acid Co., Ltd. (President Takaaki Sakai, headquartered in Songjiang District, Shanghai, China), an 

affiliate of Ajinomoto China, which is responsible for manufacturing and selling medicinal amino acids and media, is located nearby and has secured an alliance system for product sales and technical support. We provide a comprehensive range of 

high-quality media and medicinal amino acids.

An official from Ajinomoto China said, “Ajinomoto China opened a CSC equipped with the latest automatic high through put 

equipment to respond to the rapidly growing demand for media for CHO cell lines worldwide,” adding, “Including China and Korea, the United States, Europe, Japan, etc. “We will supply high-quality amino acids that comply with each pharmaceutical regulation to pharmaceutical manufacturers, cosmetics, and food manufacturers around the world.”

An official from the Ajinomoto Group said, “We have selected the biopharmaceutical media business as a key business as part of our mid-term management plan for 2020-2025.” He added, “Based on the know-how in the pharmaceutical and food amino acid business that Ajinomoto has been carrying out for more than 30 years, we will develop bioprocess technology and media. “We 

will further strengthen the global supply chain of amino acids, which are important raw materials for .”

Meanwhile, Ajinomoto Genexine, an affiliate of Ajinomoto, established a cGMP (current Good Manufacturing Practice) medium 

factory in Incheon, Korea in 2014, and manufactures cell culture medium for CHO cell lines and provides medium CMO services. 

In addition, Korea CSC was recently relocated to the Incheon Free Economic Zone, signaling the expansion of research and 

development.